Kevin N. Heller

Kevin N. Heller has a diverse work experience in the biotech and medical field. Kevin N. currently holds the position of Chief Medical Officer at Tallac Therapeutics, where they started in January 2023. Before that, they worked at BioHealth Innovation, Inc. as an Executive in Residence, providing assistance to biotech entrepreneurs funded by a grant from the Montgomery County government.

In 2020, Heller served as a Board Member on the National Leadership Council of the Society for Science. Kevin N. also held the role of Executive Vice President of Research and Development at Jasper Therapeutics from May 2020 to May 2022.

Prior to these positions, Heller was an Adjunct Professor at Yale University School of Medicine from October 2018 to October 2021. Kevin N. also served as Chief Medical Officer at NextCure, Inc. from April 2018 to May 2021.

From 2015 to 2018, Heller held the role of Vice President and Head of Antibody Clinical Development at Incyte. Kevin N. previously worked at AstraZeneca as a Senior Medical Director from May 2013 to May 2015.

Heller has also had significant experience at Bristol-Myers Squibb, where they worked from 2007 to 2013. During this time, they held various roles, including Global Lead Oncology for Search, Evaluation, and Diligence, Director of Oncology Medical Strategy, and Associate Director of Oncology & Immunology.

Before joining Bristol-Myers Squibb, Heller worked as an Instructor in Clinical Investigation at The Rockefeller University from June 2003 to July 2007.

Overall, Kevin N. Heller has had a successful career in biotech and medicine, working in leadership positions and contributing to the advancement of the field.

Kevin N. Heller earned a Bachelor of Science (BS) degree in Molecular Biophysics and Biochemistry from Yale University, which they attended from 1989 to 1993. Afterward, they pursued further education at The George Washington University School of Medicine and Health Sciences, where they obtained a Medical Doctor (MD) degree in Medicine from 1994 to 1998.